Procuritas Creates New IT Services Platform in Finland
16.6.2021 11:00:00 EEST | Business Wire | Press release
Procuritas Capital Investors VI (“Procuritas”) today announces the launch of Frendy, a new IT services platform based in Finland. The new company has been created through the acquisition of twelve IT services businesses across the country. After the transaction, Procuritas will become the majority shareholder, with the current entrepreneurial teams continuing in the day-to-day management of their local businesses with significant minority ownership of the wider company.
Frendy will deliver IT services for SME companies in Finland, a target market of more than €1 billion per annum. At inception, the company will have 160 employees in 16 locations across Finland and will be headquartered in Helsinki, with revenues in excess of €33 million.
Jussi Holopainen, Investment Manager at Procuritas, commented, “We are delighted to have completed the formation of Frendy. It is a really exciting opportunity for Procuritas to create a new company in this sizeable fragmented market currently serving SME customers in Finland.”
“With an experienced management team and board in place and potential for further acquisitions, Procuritas is looking forward to repeating another transformative growth journey through a service industry consolidation which has proven successful many times throughout its 35-year history”, says Johan Conradsson, co-Managing Partner at Procuritas.
Incoming Frendy CEO, Mikko Peltonen, added, “Frendy operates in a large market where there are a limited number of nationwide players. Bringing together these twelve businesses creates fantastic opportunities for improved customer service through consolidation and even closer local support while increasing profitability through centralised purchasing and shared systems.”
The central Frendy management team will be led by CEO Mikko Peltonen who has a background in corporate finance, including M&A advisory in the IT services space, as well as industry, and was most recently CEO of Rostek, the facade access equipment company. With a long history in the IT industry as CEO of Vincit and Jolla, and currently Chief Digital Officer at Finnair, Tomi Pienimäki becomes Chairman of the Board. Another technology industry veteran, Jyrki Rosenberg, who has led multiple global technology businesses in companies such as F-Secure, joins the Board.
About Procuritas
Procuritas is a mid-market Nordic private equity investor, building up niche market-leading companies through transformative growth in service industry consolidations, digital consumer businesses, software and select industrial sectors. As the longest-established private equity firm in the Nordics with a 35-year track record, Procuritas has carefully invested in more than 45 companies, accelerating their growth and helping them to realize their true business potential. The long-serving team is characterised by its passion for business, hands-on experience, enthusiasm, commitment to ESG-linked value creation initiatives and strong belief that they are allies in the quest to build strong and sustainable businesses. Read more at www.procuritas.com.
About Frendy
Frendy is an IT service provider for SMEs in Finland. Headquartered in Helsinki, it delivers IT support, IT security, equipment, networks, data centre and cloud services as well as document handling solutions via its local offices across the country. Frendy has been created through the acquisition of 12 companies which include Indatahouse Oy, Indata Oy, ItsPro Oy, Isoweli Oy, Tietokonemaailma Oy, Datanix Oy, Wintunix Oy, R-Office Oy, R-Office Uusimaa Oy, R-Office Itä-Suomi Oy, Soluto and Mikrovirta. Read more at www.frendy.fi.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005044/en/
Contact information
Mikko Peltonen
CEO, Frendy Oy
+358 40 520 1458 / mikko.peltonen@frendy.fi
Jussi Holopainen
Investment Manager, Procuritas
+46 70 333 55 67 / jussi.holopainen@procuritas.com
Johan Conradsson
Partner, Procuritas
+46 76 109 99 44 / johan.conradsson@procuritas.com
Media – Kepler Communications
Charlotte Balbirnie
+44 7989 528421 / CBalbirnie@keplercomms.com
Caroline Villiers
+44 7808 585184 / CVilliers@keplercomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom